MLICM
PTGX icon

Metropolitan Life Insurance Company (MetLife)’s Protagonist Therapeutics PTGX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,037
Closed -$87.9K – 1617
2024
Q1 		$87.9K Sell
3,037
-315
-9% -$8.57K ﹤0.01% 1120
2023
Q4 		$76.9K Hold
3,352
– – ﹤0.01% 1220
2023
Q3 		$55.9K Buy
3,352
+389
+13% +$7.55K ﹤0.01% 1339
2023
Q2 		$81.8K Buy
2,963
+443
+18% +$11.1K ﹤0.01% 1126
2023
Q1 		$58K Sell
2,520
-401
-14% -$6.74K ﹤0.01% 1310
2022
Q4 		$31.9K Hold
2,921
– – ﹤0.01% 1756
2022
Q3 		$24.6K Hold
2,921
– – ﹤0.01% 1912
2022
Q2 		$23.1K Hold
2,921
– – ﹤0.01% 1977
2022
Q1 		$69.2K Sell
2,921
-8,826
-75% -$249K ﹤0.01% 1409
2021
Q4 		$402K Hold
11,747
– – 0.01% 1569
2021
Q3 		$208K Buy
11,747
+195
+2% +$8.31K ﹤0.01% 2034
2021
Q2 		$518K Buy
11,552
+2,268
+24% +$74.9K 0.01% 1500
2021
Q1 		$240K Hold
9,284
– – ﹤0.01% 1889
2020
Q4 		$187K Hold
9,284
– – ﹤0.01% 1979
2020
Q3 		$182K Buy
9,284
+1,829
+25% +$34.3K ﹤0.01% 1833
2020
Q2 		$132K Buy
+7,455
New +$93.5K ﹤0.01% 2090
2019
Q4 		– Sell
-6,617
Closed -$79.5K – 2552
2019
Q3 		$79.5K Buy
+6,617
New +$83.4K ﹤0.01% 2427

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PTGX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Protagonist Therapeutics (PTGX) in Q2 2024, closing a stake of 3,037 shares — an estimated $87.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PTGX in Q3 2019 and held it in 17 quarters. The position peaked at $518K in Q2 2021. 188 funds tracked by Wall St. Rank hold PTGX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Protagonist Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,037 Protagonist Therapeutics shares in Q2 2024, an estimated $87.9K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Protagonist Therapeutics in Q3 2019 and held it in 17 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Protagonist Therapeutics position peaked at $518K in Q2 2021.
  • 188 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.